“The reality is we see the ambulatory care setting as a great strategic opportunity for Smith+Nephew,” said Mr. Kiil. “If you look at the physical footprint of our robotics platform and where we’re going with that, we obviously are performing very well in the ASC to date.”
He didn’t get into specifics about the company’s growth profile in the ASC arena, but said it was “well north” of the industry average for organic business growth in other healthcare settings.
“Total joint reconstruction in the ASC setting really only makes up between 4 percent and 6 percent of the total procedure volume today,” he said. “We see that expanding pretty substantially over the coming months and years for sure, and we’ll participate willingly in that category.”
Mr. Kiil also reported Navio sales were going well. “We have a great product and we’ve actually been converting quite a few accounts over the last few quarters and feel very strongly about the performance,” he said. The company expects the next generation of products to become available next year.
More articles on orthopedic devices:
Alphatec posts Q3 loss—6 insights
NuVasive revenue spikes 7.2% in Q3: 4 things to know
Johnson & Johnson partners on spine, trauma robot in China
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.